Aggressive NK-cell leukemia

WikiDoc Resources for Aggressive NK-cell leukemia
Articles
Most recent articles on Aggressive NK-cell leukemia Most cited articles on Aggressive NK-cell leukemia Review articles on Aggressive NK-cell leukemia Articles on Aggressive NK-cell leukemia in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Aggressive NK-cell leukemia Images of Aggressive NK-cell leukemia Photos of Aggressive NK-cell leukemia Podcasts & MP3s on Aggressive NK-cell leukemia Videos on Aggressive NK-cell leukemia
Evidence Based Medicine
Cochrane Collaboration on Aggressive NK-cell leukemia Bandolier on Aggressive NK-cell leukemia TRIP on Aggressive NK-cell leukemia
Clinical Trials
Ongoing Trials on Aggressive NK-cell leukemia at Clinical Trials.gov Trial results on Aggressive NK-cell leukemia Clinical Trials on Aggressive NK-cell leukemia at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Aggressive NK-cell leukemia NICE Guidance on Aggressive NK-cell leukemia NHS PRODIGY Guidance FDA on Aggressive NK-cell leukemia CDC on Aggressive NK-cell leukemia
Books
Books on Aggressive NK-cell leukemia
News
Aggressive NK-cell leukemia in the news Be alerted to news on Aggressive NK-cell leukemia News trends on Aggressive NK-cell leukemia
Commentary
Blogs on Aggressive NK-cell leukemia
Definitions
Definitions of Aggressive NK-cell leukemia
Patient Resources / Community
Patient resources on Aggressive NK-cell leukemia Discussion groups on Aggressive NK-cell leukemia Patient Handouts on Aggressive NK-cell leukemia Directions to Hospitals Treating Aggressive NK-cell leukemia Risk calculators and risk factors for Aggressive NK-cell leukemia
Healthcare Provider Resources
Symptoms of Aggressive NK-cell leukemia Causes & Risk Factors for Aggressive NK-cell leukemia Diagnostic studies for Aggressive NK-cell leukemia Treatment of Aggressive NK-cell leukemia
Continuing Medical Education (CME)
CME Programs on Aggressive NK-cell leukemia
International
Aggressive NK-cell leukemia en Espanol Aggressive NK-cell leukemia en Francais
Business
Aggressive NK-cell leukemia in the Marketplace Patents on Aggressive NK-cell leukemia
Experimental / Informatics
List of terms related to Aggressive NK-cell leukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Historical Perspective

• Aggressive NK-cell leukemia was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of aggressive NK-cell leukemia.
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose aggressive NK-cell leukemia.

Classification

• Aggressive NK-cell leukemia may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of aggressive NK-cell leukemia include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of aggressive NK-cell leukemia is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of aggressive NK-cell leukemia, involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of aggressive NK-cell leukemia.
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of aggressive NK-cell leukemia.

Causes

• Aggressive NK-cell leukemia may be caused by either [cause1], [cause2], or [cause3].
• Aggressive NK-cell leukemia is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for aggressive NK-cell leukemia.

Differentiating Aggressive NK-cell Leukemia from Other Diseases

• Aggressive NK-cell leukemia must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of aggressive NK-cell leukemia is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of aggressive NK-cell leukemia was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop aggressive NK-cell leukemia.

• Aggressive NK-cell leukemia is more commonly observed among patients aged [age range] years old.
• Aggressive NK-cell leukemia is more commonly observed among [elderly patients/young patients/children].

Gender

• Aggressive NK-cell leukemia affects men and women equally.

• [Gender 1] are more commonly affected with aggressive NK-cell leukemia than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for aggressive NK-cell leukemia.

• Aggressive NK-cell leukemia usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop aggressive NK-cell leukemia.

Risk Factors

• Common risk factors in the development of aggressive NK-cell leukemia are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with aggressive NK-cell leukemia remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with aggressive NK-cell leukemia may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of aggressive NK-cell leukemia include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with aggressive NK-cell leukemia is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of aggressive NK-cell leukemia is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• Aggressive NK-cell leukemia is usually asymptomatic.
• Symptoms of aggressive NK-cell leukemia may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with aggressive NK-cell leukemia usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with aggressive NK-cell leukemia.

• A [positive/negative] [test name] is diagnostic of aggressive NK-cell leukemia.
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of aggressive NK-cell leukemia.
• Other laboratory findings consistent with the diagnosis of aggressive NK-cell leukemia include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with aggressive NK-cell leukemia.

• [Imaging study 1] is the imaging modality of choice for aggressive NK-cell leukemia.
• On [imaging study 1], aggressive NK-cell leukemia is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• Aggressive NK-cell leukemia may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for aggressive NK-cell leukemia; the mainstay of therapy is supportive care.

• The mainstay of therapy for aggressive NK-cell leukemia is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for aggressive NK-cell leukemia.
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of aggressive NK-cell leukemia.
• [Surgical procedure] can only be performed for patients with [disease stage] aggressive NK-cell leukemia.

Prevention

• There are no primary preventive measures available for aggressive NK-cell leukemia.

• Effective measures for the primary prevention of aggressive NK-cell leukemia include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with aggressive NK-cell leukemia are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].